Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA, dated February 20, 2020, serves to furnish the U.S. Securities and Exchange Commission with the Company's press release and financial figures regarding its fourth quarter and full fiscal year 2019 results, originally announced on February 19, 2020.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (Exhibit 99.1 and Exhibit 99.2) which are referenced but not included in the provided text.
The Company utilizes the following non-GAAP financial measures to supplement IFRS results:
- EBITDA (operating income excluding interest, taxes, depreciation, and amortization)
- Delivered operating income (earnings before interest and taxes)
- Free cash flow
- Results presented in constant currency
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It notes that the attached press release contains the specific financial results and reconciliations necessary to assess performance changes.
Guidance, Outlook, and Risks
The filing states that the non-GAAP measures are provided to enhance understanding of current performance and future prospects. However, the text does not contain specific guidance, management commentary on future outlook, or a detailed list of risks and contingencies beyond the standard regulatory disclaimers regarding the use of non-GAAP measures.
Investor Verification Checklist
- Verify the specific Q4 and full-year 2019 revenue and profit figures in the attached Exhibit 99.2.
- Review the reconciliation of non-GAAP measures (EBITDA, free cash flow) to IFRS standards in the attached press release.
- Confirm the impact of currency fluctuations by comparing reported results with constant currency results.
- Examine the full press release for any specific operational updates or strategic shifts not detailed in this cover letter.